Cargando…
Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?
Purpose. The association between transarterial chemoembolization- (TACE-) induced HCC tumor necrosis measured by the modified Response Evaluation Criteria In Solid Tumors (mRECIST) and patient survival is poorly defined. We hypothesize that survival will be superior in HCC patients with increased TA...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754482/ https://www.ncbi.nlm.nih.gov/pubmed/26949394 http://dx.doi.org/10.1155/2016/4692139 |
_version_ | 1782416029750657024 |
---|---|
author | Haywood, Nathan Gennaro, Kyle Obert, John Sauer, Paul F. Redden, David T. Zarzour, Jessica Smith, J. Kevin Bolus, David Saddekni, Souheil Aal, Ahmed Kamel Abdel Gray, Stephen White, Jared Eckhoff, Devin E. DuBay, Derek A. |
author_facet | Haywood, Nathan Gennaro, Kyle Obert, John Sauer, Paul F. Redden, David T. Zarzour, Jessica Smith, J. Kevin Bolus, David Saddekni, Souheil Aal, Ahmed Kamel Abdel Gray, Stephen White, Jared Eckhoff, Devin E. DuBay, Derek A. |
author_sort | Haywood, Nathan |
collection | PubMed |
description | Purpose. The association between transarterial chemoembolization- (TACE-) induced HCC tumor necrosis measured by the modified Response Evaluation Criteria In Solid Tumors (mRECIST) and patient survival is poorly defined. We hypothesize that survival will be superior in HCC patients with increased TACE-induced tumor necrosis. Materials and Methods. TACE interventions were retrospectively reviewed. Tumor response was quantified via dichotomized (responders and nonresponders) and the four defined mRECIST categories. Results. Median survival following TACE was significantly greater in responders compared to nonresponders (20.8 months versus 14.9 months, p = 0.011). Survival outcomes also significantly varied among the four mRECIST categories (p = 0.0003): complete, 21.4 months; partial, 20.8; stable, 16.8; and progressive, 7.73. Only progressive disease demonstrated significantly worse survival when compared to complete response. Multivariable analysis showed that progressive disease, increasing total tumor diameter, and non-Child-Pugh class A were independent predictors of post-TACE mortality. Conclusions. Both dichotomized (responders and nonresponders) and the four defined mRECIST responses to TACE in patients with HCC were predictive of survival. The main driver of the survival analysis was poor survival in the progressive disease group. Surprisingly, there was small nonsignificant survival benefit between complete, partial, and stable disease groups. These findings may inform HCC treatment decisions following first TACE. |
format | Online Article Text |
id | pubmed-4754482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-47544822016-03-06 Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? Haywood, Nathan Gennaro, Kyle Obert, John Sauer, Paul F. Redden, David T. Zarzour, Jessica Smith, J. Kevin Bolus, David Saddekni, Souheil Aal, Ahmed Kamel Abdel Gray, Stephen White, Jared Eckhoff, Devin E. DuBay, Derek A. J Oncol Clinical Study Purpose. The association between transarterial chemoembolization- (TACE-) induced HCC tumor necrosis measured by the modified Response Evaluation Criteria In Solid Tumors (mRECIST) and patient survival is poorly defined. We hypothesize that survival will be superior in HCC patients with increased TACE-induced tumor necrosis. Materials and Methods. TACE interventions were retrospectively reviewed. Tumor response was quantified via dichotomized (responders and nonresponders) and the four defined mRECIST categories. Results. Median survival following TACE was significantly greater in responders compared to nonresponders (20.8 months versus 14.9 months, p = 0.011). Survival outcomes also significantly varied among the four mRECIST categories (p = 0.0003): complete, 21.4 months; partial, 20.8; stable, 16.8; and progressive, 7.73. Only progressive disease demonstrated significantly worse survival when compared to complete response. Multivariable analysis showed that progressive disease, increasing total tumor diameter, and non-Child-Pugh class A were independent predictors of post-TACE mortality. Conclusions. Both dichotomized (responders and nonresponders) and the four defined mRECIST responses to TACE in patients with HCC were predictive of survival. The main driver of the survival analysis was poor survival in the progressive disease group. Surprisingly, there was small nonsignificant survival benefit between complete, partial, and stable disease groups. These findings may inform HCC treatment decisions following first TACE. Hindawi Publishing Corporation 2016 2016-02-02 /pmc/articles/PMC4754482/ /pubmed/26949394 http://dx.doi.org/10.1155/2016/4692139 Text en Copyright © 2016 Nathan Haywood et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Haywood, Nathan Gennaro, Kyle Obert, John Sauer, Paul F. Redden, David T. Zarzour, Jessica Smith, J. Kevin Bolus, David Saddekni, Souheil Aal, Ahmed Kamel Abdel Gray, Stephen White, Jared Eckhoff, Devin E. DuBay, Derek A. Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title_full | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title_fullStr | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title_full_unstemmed | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title_short | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
title_sort | does the degree of hepatocellular carcinoma tumor necrosis following transarterial chemoembolization impact patient survival? |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754482/ https://www.ncbi.nlm.nih.gov/pubmed/26949394 http://dx.doi.org/10.1155/2016/4692139 |
work_keys_str_mv | AT haywoodnathan doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT gennarokyle doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT obertjohn doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT sauerpaulf doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT reddendavidt doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT zarzourjessica doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT smithjkevin doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT bolusdavid doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT saddeknisouheil doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT aalahmedkamelabdel doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT graystephen doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT whitejared doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT eckhoffdevine doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival AT dubaydereka doesthedegreeofhepatocellularcarcinomatumornecrosisfollowingtransarterialchemoembolizationimpactpatientsurvival |